{"id":10028,"date":"2015-03-03T09:39:28","date_gmt":"2015-03-03T09:39:28","guid":{"rendered":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/"},"modified":"2019-02-12T12:28:23","modified_gmt":"2019-02-12T12:28:23","slug":"apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva","status":"publish","type":"post","link":"https:\/\/www.moor.co.uk\/zh-cn\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/","title":{"rendered":"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122"},"content":{"rendered":"

Moor Instruments is proud to have supplied Apricus Biosciences (NexMed U.S.A. Inc)\u00a0with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy. Apricus specified moorLDLS<\/a> laser Doppler line scanning to help demonstrate alterations in microvascular flow following a standardized cold challenge. “Raynaud’s phenomenon is a near universal feature of scleroderma and causes pain, loss of hand function and is associated with fingertip ulcerations and loss of finger substance. A topical therapy such as RayVa has the ability to improve blood flow locally without systemic adverse effects and has the potential to alleviate symptoms and possibly prevent finger injury,” said Dr. James R. Seibold, an internationally recognized researcher in both scleroderma and Raynaud’s phenomenon and the Principal Member of Scleroderma Research Consultants, LLC.<\/p>\n

The full press release from Apricus can be found here<\/a>.<\/p>\n

For more information on the clinical trial click here<\/a>.<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Moor Instruments is proud to h […]<\/p>\n","protected":false},"author":2,"featured_media":10029,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1535],"tags":[2305,2577],"class_list":["post-10028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-zh-cn","tag-apricus-biosciences-zh-cn","tag-raynauds-phenomenon-zh-cn-2"],"acf":[],"yoast_head":"\nApricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122<\/title>\n<meta name=\"description\" content=\"Moor Instruments is proud to have supplied Apricus Biosciences with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122\" \/>\n<meta property=\"og:description\" content=\"Moor Instruments is proud to have supplied Apricus Biosciences with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\" \/>\n<meta property=\"og:site_name\" content=\"Moor Instruments\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MoorInstruments\" \/>\n<meta property=\"article:published_time\" content=\"2015-03-03T09:39:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-12T12:28:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"737\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Jay Sweetman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@moor_hq\" \/>\n<meta name=\"twitter:site\" content=\"@moor_hq\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jay Sweetman\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\"},\"author\":{\"name\":\"Jay Sweetman\",\"@id\":\"https:\/\/www.moor.co.uk\/#\/schema\/person\/54255f7fcb09aa80d2f4f8e0cf59d927\"},\"headline\":\"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122\",\"datePublished\":\"2015-03-03T09:39:28+00:00\",\"dateModified\":\"2019-02-12T12:28:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\"},\"wordCount\":164,\"publisher\":{\"@id\":\"https:\/\/www.moor.co.uk\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg\",\"keywords\":[\"Apricus Biosciences\",\"Raynaud's Phenomenon\"],\"articleSection\":[\"Research\"],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\",\"url\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\",\"name\":\"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122\",\"isPartOf\":{\"@id\":\"https:\/\/www.moor.co.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg\",\"datePublished\":\"2015-03-03T09:39:28+00:00\",\"dateModified\":\"2019-02-12T12:28:23+00:00\",\"description\":\"Moor Instruments is proud to have supplied Apricus Biosciences with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy\",\"breadcrumb\":{\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage\",\"url\":\"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg\",\"contentUrl\":\"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg\",\"width\":960,\"height\":737},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.moor.co.uk\/zh-cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research\",\"item\":\"https:\/\/www.moor.co.uk\/en-us\/news\/category\/research-en-us\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.moor.co.uk\/#website\",\"url\":\"https:\/\/www.moor.co.uk\/\",\"name\":\"Moor Instruments\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.moor.co.uk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.moor.co.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.moor.co.uk\/#organization\",\"name\":\"Moor Instruments\",\"url\":\"https:\/\/www.moor.co.uk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\/\/www.moor.co.uk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.moorclinical.com\/wp-content\/uploads\/2018\/10\/logo-30.png\",\"contentUrl\":\"https:\/\/www.moorclinical.com\/wp-content\/uploads\/2018\/10\/logo-30.png\",\"width\":298,\"height\":49,\"caption\":\"Moor Instruments\"},\"image\":{\"@id\":\"https:\/\/www.moor.co.uk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MoorInstruments\",\"https:\/\/x.com\/moor_hq\",\"https:\/\/www.linkedin.com\/company\/2523249\",\"https:\/\/www.youtube.com\/user\/MoorInstruments\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.moor.co.uk\/#\/schema\/person\/54255f7fcb09aa80d2f4f8e0cf59d927\",\"name\":\"Jay Sweetman\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122","description":"Moor Instruments is proud to have supplied Apricus Biosciences with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/","og_locale":"zh_CN","og_type":"article","og_title":"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122","og_description":"Moor Instruments is proud to have supplied Apricus Biosciences with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy","og_url":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/","og_site_name":"Moor Instruments","article_publisher":"https:\/\/www.facebook.com\/MoorInstruments","article_published_time":"2015-03-03T09:39:28+00:00","article_modified_time":"2019-02-12T12:28:23+00:00","og_image":[{"width":960,"height":737,"url":"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg","type":"image\/jpeg"}],"author":"Jay Sweetman","twitter_card":"summary_large_image","twitter_creator":"@moor_hq","twitter_site":"@moor_hq","twitter_misc":{"\u4f5c\u8005":"Jay Sweetman","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"1 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#article","isPartOf":{"@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/"},"author":{"name":"Jay Sweetman","@id":"https:\/\/www.moor.co.uk\/#\/schema\/person\/54255f7fcb09aa80d2f4f8e0cf59d927"},"headline":"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122","datePublished":"2015-03-03T09:39:28+00:00","dateModified":"2019-02-12T12:28:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/"},"wordCount":164,"publisher":{"@id":"https:\/\/www.moor.co.uk\/#organization"},"image":{"@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage"},"thumbnailUrl":"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg","keywords":["Apricus Biosciences","Raynaud's Phenomenon"],"articleSection":["Research"],"inLanguage":"zh-Hans"},{"@type":"WebPage","@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/","url":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/","name":"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122","isPartOf":{"@id":"https:\/\/www.moor.co.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage"},"image":{"@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage"},"thumbnailUrl":"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg","datePublished":"2015-03-03T09:39:28+00:00","dateModified":"2019-02-12T12:28:23+00:00","description":"Moor Instruments is proud to have supplied Apricus Biosciences with laser Doppler imaging kits for their Phase 2a clinical trial of their topical RayVa\u2122 therapy","breadcrumb":{"@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#primaryimage","url":"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg","contentUrl":"https:\/\/www.moor.co.uk\/wp-content\/uploads\/2015\/03\/moorLDLS-Imaging.jpg","width":960,"height":737},{"@type":"BreadcrumbList","@id":"https:\/\/www.moor.co.uk\/news\/apricus-biosciences-announces-first-patient-enrolled-in-phase-2a-clinical-trial-for-rayva\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.moor.co.uk\/zh-cn\/"},{"@type":"ListItem","position":2,"name":"Research","item":"https:\/\/www.moor.co.uk\/en-us\/news\/category\/research-en-us\/"},{"@type":"ListItem","position":3,"name":"Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa\u2122"}]},{"@type":"WebSite","@id":"https:\/\/www.moor.co.uk\/#website","url":"https:\/\/www.moor.co.uk\/","name":"Moor Instruments","description":"","publisher":{"@id":"https:\/\/www.moor.co.uk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.moor.co.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Organization","@id":"https:\/\/www.moor.co.uk\/#organization","name":"Moor Instruments","url":"https:\/\/www.moor.co.uk\/","logo":{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.moor.co.uk\/#\/schema\/logo\/image\/","url":"https:\/\/www.moorclinical.com\/wp-content\/uploads\/2018\/10\/logo-30.png","contentUrl":"https:\/\/www.moorclinical.com\/wp-content\/uploads\/2018\/10\/logo-30.png","width":298,"height":49,"caption":"Moor Instruments"},"image":{"@id":"https:\/\/www.moor.co.uk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MoorInstruments","https:\/\/x.com\/moor_hq","https:\/\/www.linkedin.com\/company\/2523249","https:\/\/www.youtube.com\/user\/MoorInstruments"]},{"@type":"Person","@id":"https:\/\/www.moor.co.uk\/#\/schema\/person\/54255f7fcb09aa80d2f4f8e0cf59d927","name":"Jay Sweetman"}]}},"_links":{"self":[{"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/posts\/10028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/comments?post=10028"}],"version-history":[{"count":0,"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/posts\/10028\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/media\/10029"}],"wp:attachment":[{"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/media?parent=10028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/categories?post=10028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.moor.co.uk\/zh-cn\/wp-json\/wp\/v2\/tags?post=10028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}